once-weekly semaglutide in persons with obesity and knee osteoarthritis "Among participants with obesity and knee osteoarthritis with moderate-to-severe pain, treatment with once-weekly injectable semaglutide resulted in significantly greater obesity and knee osteoarthritis with

Tesamorelin: Reduces visceral fat, improves body composition, and supports a leaner physique

Most headaches associated with GLP-1 weight loss injections are mild to moderate and tend to occur during the initial weeks of treatment or following dose escalation

Specification of Target Trials Study Overview We compared semaglutide or tirzepatide with other antidiabetic medications for the associated risk of optic nerve and visual pathway disorders in patients with type 2 diabetes who had no prior diagnosis of any eye disorder (determined by the absence of International Statistical Classification of Diseases and Related Health Problems, Tenth Revision [ ICD-10 ] codes H00-H59, Diseases of the eye and adnexa, documented in EHRs) using a target trial emulation framework

Possibly, but with extra caution